Want to see HK:2162 full AI Analyst Report?
2162 Stock Chart & Stats
HK$62.80
HK$0.80(2.86%)
At close: 4:00 PM EST
HK$62.80
HK$0.80(2.86%)
Day’s Range― - ―
52-Week RangeHK$44.66 - HK$89.75
Previous CloseN/A
Volume918.50K
Average Volume (3M)1.75M
Market Cap
HK$21.04B
Enterprise ValueHK$17.31K
Total Cash (Recent Filing)HK$3.24B
Total Debt (Recent Filing)HK$696.57M
Price to Earnings (P/E)22.5
Beta0.83
Next Earnings
Mar 30, 2027EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.78
Shares Outstanding298,735,570
10 Day Avg. Volume1,466,341
30 Day Avg. Volume1,745,417
Financial Highlights & Ratios
PEG Ratio4.62
Price to Book (P/B)4.74
Price to Sales (P/S)18.85
P/FCF Ratio-12.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$107.32Price Target Upside70.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)2.76
Revenue Forecast (FY)HK$1.53B
Bulls Say, Bears Say
Bulls Say
Strong Equity BaseA sizable positive equity base and moderate leverage provide financial support for continued investment in drug development and commercialization. This relative balance-sheet strength can improve resilience and preserve strategic flexibility as the company funds programs through a loss-making period.
High Gross ProfitabilityThe high gross margin indicates that the company’s products and development outputs can generate substantial value after direct costs. If revenue stabilizes and operating expenses become more efficient, this gross-profit foundation could support meaningful margin improvement over time.
Substantial Revenue Scale-upRevenue has expanded materially over several years, demonstrating that the business has progressed beyond an early-stage revenue base. This larger commercial scale can provide a stronger platform for product investment, partnerships, and eventual operating leverage if growth resumes.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow shows that the company is consuming substantial cash to operate and invest. Continued burn can increase reliance on financing capacity, constrain capital allocation, and reduce flexibility if losses or development spending remain elevated.
Deep Operating LossesVery negative operating and net margins indicate that current revenue is insufficient to cover the company’s operating and development cost base. Until expenses scale more effectively or revenue improves, sustained losses will weigh on shareholder returns and financial durability.
Revenue ContractionThe 2025 revenue decline, following uneven growth in prior years, points to volatility in the company’s commercial trajectory. A shrinking top line makes it harder to absorb fixed research and operating costs and delays the path toward breakeven and self-funded growth.
Keymed Biosciences, Inc. News
2162 FAQ
What was Keymed Biosciences, Inc.’s price range in the past 12 months?
Keymed Biosciences, Inc. lowest stock price was HK$44.66 and its highest was HK$89.75 in the past 12 months.
What is Keymed Biosciences, Inc.’s market cap?
Keymed Biosciences, Inc.’s market cap is HK$21.04B.
When is Keymed Biosciences, Inc.’s upcoming earnings report date?
Keymed Biosciences, Inc.’s upcoming earnings report date is Mar 30, 2027 which is in 181 days.
How were Keymed Biosciences, Inc.’s earnings last quarter?
Keymed Biosciences, Inc. released its earnings results on Aug 20, 2026. The company reported HK$5.015 earnings per share for the quarter, missing the consensus estimate of HK$5.377 by -HK$0.362.
Is Keymed Biosciences, Inc. overvalued?
According to Wall Street analysts Keymed Biosciences, Inc.’s price is currently Undervalued.
Does Keymed Biosciences, Inc. pay dividends?
Keymed Biosciences, Inc. does not currently pay dividends.
What is Keymed Biosciences, Inc.’s EPS estimate?
Keymed Biosciences, Inc.’s EPS estimate is -0.65.
How many shares outstanding does Keymed Biosciences, Inc. have?
Keymed Biosciences, Inc. has 298,735,570 shares outstanding.
What happened to Keymed Biosciences, Inc.’s price movement after its last earnings report?
Keymed Biosciences, Inc. reported an EPS of HK$5.015 in its last earnings report, missing expectations of HK$5.377. Following the earnings report the stock price went up 0.909%.
Which hedge fund is a major shareholder of Keymed Biosciences, Inc.?
Currently, no hedge funds are holding shares in HK:2162
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Keymed Biosciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
29.16%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Keymed Biosciences, Inc.
Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China (formerly known as 2Health Biosciences, Inc.), specializes in the research and development of innovative biological treatments, primarily targeting autoimmune and oncology diseases. A cornerstone of their pipeline is CM310, their lead product candidate, which is currently being developed for the management of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). Complementing this, the company is also progressing CM326, a monoclonal antibody designed to inhibit thymic stromal lymphopoietin, for similar indications such as AD, CRSwNP, asthma, and COPD. In the realm of oncology, Keymed is developing CMG901 for solid tumors, particularly those affecting the stomach and gastroesophageal junction. Another significant candidate, CM313, is a humanized monoclonal antibody slated for the treatment of relapsed or refractory multiple myeloma, lymphoma, other blood cancers, and systemic lupus erythematosus. Their extensive portfolio further includes MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectin-associated serine protease-2; CM355, intended for relapsed or refractory non-Hodgkin's lymphoma; CM336, for multiple myeloma; CM350, for various solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody.
2162 Stock 12 Month Forecast
Average Price Target
HK$107.32
▲(70.89% Upside)
Technical Analysis
Zai Lab Ltd
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―